União Química acquires a new manufacturing facility from Bayer, enhancing its production capabilities and cementing its position as the leader in the Latin American contraceptives market.

Target Information

União Química has established itself as a major player in the pharmaceutical industry, primarily recognized for its leading contraceptive product, Ciclo 21. The company has recently acquired a new manufacturing facility and expanded its product portfolio to include nine additional products, solidifying its position as a leader in the oral hormonal contraceptives market in Latin America.

The newly acquired facility, located in São Paulo, Brazil, spans over 15,000 square meters and is dedicated to the production of female hormones, contraceptives, and hormone replacement therapies. With a production capacity of approximately 70 million blisters annually, this factory significantly boosts União Química's manufacturing capabilities.

Industry Overview

The contraceptive market in Brazil and wider Latin America has shown substantial growth over the past few years, driven by increasing awareness of reproductive health and f